A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Completed · Phase 1 · NCT05916560
Conditions: Healthy, Hepatic Insufficiency
At a glance
- Research payments reported, 2025
- $639,487
- U.S. investigators named
- 4
- Sites paid
- 6
- Planned or actual enrollment
- 43
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3437943 (drug)
- Dates
- Started 2023-07-13; completion 2025-03-02
- Results posted
- Not yet
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.
From ClinicalTrials.gov, last updated 2025-04-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $639,487 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Bruce G. Rankin, D. O. Family Medicine · Deland, FL
- Naim Alkhouri, MD Gastroenterology · Westlake, OH
- Eric J. Lawitz, M.D. Gastroenterology · San Antonio, TX
- Madhavi Rudraraju, M.D. Hepatology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- American Research Corp Inc $488,989
- Pinnacle Clinical Research LLC $86,116
- University Clinical Research Deland LLC $29,269
- Institute for Liver Health LLC $20,000
- Arizona Research Center $13,900
- The Texas Liver Institute $1,214
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.